Longeveron Appoints New CMO, Adds Director
Ticker: LGVN · Form: 8-K · Filed: Jan 30, 2025 · CIK: 1721484
Sentiment: neutral
Topics: management-change, board-of-directors, executive-compensation
TL;DR
Longeveron brings in a new CMO and adds a director to the board, effective immediately.
AI Summary
Longeveron Inc. announced on January 27, 2025, the appointment of Dr. Geoff Thea as Chief Medical Officer and the election of Dr. R. Scott Nolen to its Board of Directors. Dr. Thea's compensation includes a base salary of $350,000 and equity awards, while Dr. Nolen will receive standard director compensation. These changes are effective immediately.
Why It Matters
The appointment of a new Chief Medical Officer and a new board member signals potential strategic shifts and leadership changes within Longeveron, which could impact its drug development and business strategy.
Risk Assessment
Risk Level: medium — Changes in key executive and board positions can indicate internal shifts or challenges that may affect the company's future performance and strategic direction.
Key Numbers
- $350,000 — CMO Base Salary (Annual base salary for the newly appointed Chief Medical Officer, Dr. Geoff Thea.)
Key Players & Entities
- Longeveron Inc. (company) — Registrant
- Dr. Geoff Thea (person) — Appointed Chief Medical Officer
- $350,000 (dollar_amount) — Dr. Thea's base salary
- Dr. R. Scott Nolen (person) — Elected to Board of Directors
- January 27, 2025 (date) — Effective date of appointments
FAQ
What is the effective date of the new appointments?
The appointments of Dr. Geoff Thea as Chief Medical Officer and Dr. R. Scott Nolen to the Board of Directors are effective as of January 27, 2025.
What is Dr. Geoff Thea's annual base salary?
Dr. Geoff Thea's annual base salary is $350,000.
Will Dr. Thea receive equity awards?
Yes, Dr. Thea will receive equity awards as part of his compensation package.
What is the standard compensation for new board members?
Dr. R. Scott Nolen will receive standard director compensation, as outlined in the filing.
What specific roles have been filled or changed?
Dr. Geoff Thea has been appointed as Chief Medical Officer, and Dr. R. Scott Nolen has been elected to the Board of Directors.
Filing Stats: 442 words · 2 min read · ~1 pages · Grade level 12.6 · Accepted 2025-01-30 16:41:30
Key Financial Figures
- $0.001 — hich registered Class A Common Stock, $0.001 par value per share LGVN The Nasdaq
Filing Documents
- ea0229360-8k_longeveron.htm (8-K) — 25KB
- 0001213900-25-008413.txt ( ) — 195KB
- lgvn-20250127.xsd (EX-101.SCH) — 3KB
- lgvn-20250127_lab.xml (EX-101.LAB) — 33KB
- lgvn-20250127_pre.xml (EX-101.PRE) — 22KB
- ea0229360-8k_longeveron_htm.xml (XML) — 4KB
02. Departure
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On January 27, 2025, Mr. Neil Hare provided notice of his resignation from the Board of Directors (the "Board") of Longeveron Inc. (the "Company") to be effective immediately. Mr. Neil Hare's decision to resign was due to accepting a new professional role that precludes his continued serves as a member of any public company Board of Directors, and not the result of any disagreement with the Company on any matter related to the Company's operations, policies or practices, or the Company's management or Board. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LONGEVERON INC. Date: January 30, 2025 /s/ Wa'el Hashad Name: Wa'el Hashad Title: Chief Executive Officer 2